Company Information


Agenus is an immuno-oncology company focused on the discovery and development of potentially revolutionary new treatments that leverage the body’s immune system to fight cancer and infectious diseases. Agenus has established a highly integrated approach to validate targets of interest, identify therapeutically relevant biomarkers, engineer highly differentiated therapies, and explore novel immunotherapy combinations. The company supports discovery and development efforts with wholly-owned, advanced clinical and manufacturing capabilities and pursues strategic partnerships as means of accelerating development timelines. The company currently has active collaborations with several leaders in the oncology field, including Bristol Myers Squibb, Merck, Gilead and Incyte. Through its subsidiaries, MiNK therapeutics and SaponiQx, Agenus is pursuing allogeneic cell therapies and vaccine adjuvants, respectively.

Press Releases
May 25, 2023
LEXINGTON, Mass. --(BUSINESS WIRE)--May 25, 2023-- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today announced that Dr. Garo Armen , Chairman and CEO, will participate in a fireside chat and investor one-on-ones
May 09, 2023
At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median of four prior treatments, more than double the survival rate reported for available treatments

btn News

Events and Presentations

btn Events